MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced that its Mosaic® bioprosthetic heart valve has demonstrated positive performance results at 12 years in a study published online in The Journal of Thoracic and Cardiovascular Surgery. The Mosaic valve was evaluated in patients who had aortic valve replacement (AVR) and mitral valve replacement (MVR), and with 12 years of follow-up, the study revealed a freedom from structural valve deterioration of 93.3 percent of AVR patients 60 years and older and in 95.3 percent of MVR patients 70 years and older. In addition, hemodynamic performance data showed stability up to 10 years, indicating durability of the Mosaic bioprosthesis over time.
